Purchase this article with an account.
David Albers, Guorong Li, William K McVicar, W Daniel Stamer; Intraocular pressure lowering following topical (ocular) delivery of trabodenoson: Effects of preservative and age in living mice.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2107.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Trabodenoson is a selective adenosine A1 mimetic previously shown to lower intraocular pressure (IOP) in rabbits, monkeys and humans. We have previously reported that trabodenoson significantly lowers IOP in 3 month old mice by increasing conventional outflow facility. The purpose of the current study was to test IOP-lowering efficacy of trabodenoson in aged mice. Further, we investigated whether a preservative-free formulation of trabodenoson impacts the magnitude of IOP lowering.
Three month or one year old C57Bl6J male and female mice received once daily topical administrations of 6% trabodenoson in the right eye and vehicle in the left eye for 7 days. In experiments involving the evaluation of preservative-free formulation, preservative-free vehicle was used. In all groups of mice, IOPs were measured daily in both eyes by rebound tonometry, 30 min prior to drug/vehicle administration.
In one year old mice, a significant lowering in IOP was observed in trabodenoson-treated eyes as compared to vehicle-treated eyes after 7 days of evaluation. IOPs decreased up to 3.0±0.81 mean ± SEM mmHg as compared to vehicle (p<0.05). Despite lower mean IOPs in older mice (16 versus 20 mmHg), this IOP reduction in older mice was similar to IOP changes in 3 month old mice (3.64±0.62 as compared to vehicle, p<0.05). Interestingly, once daily 6% trabodenoson formulated in a preservative-free suspension reduced IOP approximately 3.1±1.86 mmHg as compared to vehicle, similar to the IOP lowering effects of trabodenoson formulated in a preservative-containing suspension.
Trabodenoson reduced IOP equivalently in both 3 month and one year old mice. Furthermore, the IOP-lowering capabilities of trabodenoson are similar in preservative-free formulations as compared to preservative-containing formulations.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only